MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報，我們不為任何個人用途提供產(chǎn)品和服務(wù)。

MKK7-COV-9

CAS No. : 2283355-59-7

產(chǎn)品活性：MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC₅₀ of 4.98 μM.

研究領(lǐng)域：MAPK/ERK Pathway

作用靶點：p38 MAPK

In Vitro: Due to poor permeability, the?piperidine?analogs MKK7-COV-10 and MKK7-COV-11 proves to be inactive in ICW in 3T3 cells, as well as the carboxylic acid MKK7-COV-8. In contrast, as an?amide?counterpart , MKK7-COV-9, retains activity (EC₅₀=4.06?μM) and furthermore now provides a new vector for further?derivatization.
MKK7-COV-9 (10?μM; 48 hours) shows limited cytotoxic effect only at the highest tested concentration. Only one cell line, HCT116, displayed?half-maximal lethal dose (LD₅₀)<10?μM for these two compounds.
MKK7-COV-9?(10?μM; 2?hr pre-incubation) is able to inhibit 60% of the CD86⁺ response in response to LPS stimulation,?in primary mouse B cells?, except the negative control MKK7-NEG-1.
JNK is known to mediate activation of B cells in response to?lipopolysaccharide (LPS; HY-D1056) through the?TLR4?signaling pathway.
MKK7-COV-9 (0-10 μM; 2?hr pre-incubation) is able to mediate activation of B cells in response to?LPS through the?TLR4?signaling pathway, it shows a dose-response curves for inhibition of LPS induced activation and exhibits an EC₅₀ value of 4.98 μM.(EC₅₀=4.98 μM for MKK7-COV-12; EC₅₀>10 μM for MKK7-COV-7; EC₅₀=2.23 μM for JNK-IN-8).

相關(guān)產(chǎn)品：Covalent Screening Library Plus  |  Bioactive Compound Library Plus  |  Immunology/Inflammation Compound Library  |  Kinase Inhibitor Library  |  MAPK Compound Library  |  Anti-Cancer Compound Library  |  Covalent Screening Library  |  Reprogramming Compound Library  |  Oxygen Sensing Compound Library  |  Pyroptosis Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Cancer Metabolism Compound Library  |  Neurodegenerative Disease-related Compound Library  |  Anti-Obesity Compound Library  |  Angiogenesis-Related Compound Library  |  Antidepressant Compound Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Heterocyclic Compound Library  |  Pain-Related Compound Library  |  Membrane Protein-targeted Compound Library  |  Bisabolangelone  |  4-Hydroxylonchocarpin  |  TLR4/NF-κB/MAPK-IN-1  |  Broussonin E  |  L-threo-Sphingosine  |  SB 242235  |  Hydrangenol  |  EGF-R (661-681) T669 Peptide  |  TA-01  |  AMG-548 hydrochloride  |  JX401  |  Ganoderterpene A  |  VX-702  |  Esculin  |  R1487 Hydrochloride  |  Emprumapimod  |  BMS-751324  |  p38α inhibitor 3  |  Anti-inflammatory agent 7  |  Atraric acid  |  BMS-582949 hydrochloride  |  Ferulic acid methyl ester  |  Dilmapimod  |  Gossypetin  |  Pamapimod  |  Andrograpanin  |  (Rac)-Hesperetin  |  Lucidone  |  PF-03715455  |  AMG-47a

熱門產(chǎn)品線：重組蛋白  |  化合物庫  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物  |  寡核苷酸  |  抗體  |  點擊化學(xué)

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Fluorescent Dye  |  PROTAC  |  Isotope-Labeled Compounds  |  Oligonucleotides  |  Antibodies  |  Click Chemistry

品牌介紹:
•   MCE (MedChemExpress) 擁有200 多種*僅有化合物庫，我們致力于為*科研客戶提供前沿的高品質(zhì)小分子活性化合物；
•   50,000 多種高選擇性抑制劑、激動劑涉及各熱門信號通路及疾病領(lǐng)；
•   產(chǎn)品種類涵蓋各種重組蛋白，多肽，常用試劑盒 ，更有 PROTAC、ADC 等特色產(chǎn)品，廣泛應(yīng)用于新藥研發(fā)、生命科學(xué)等科研項目；
•   提供虛擬篩選，離子通道篩選，代謝組學(xué)分析檢測分析，藥物篩選等專業(yè)技術(shù)服務(wù)；
•   設(shè)有專業(yè)的實驗中心和嚴(yán)格的質(zhì)控、驗證體系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各項質(zhì)檢報告，確保產(chǎn)品的高純度、高品質(zhì)；
•   產(chǎn)品的生物活性多經(jīng)各國客戶實驗驗證；
•   Nature, Cell, Science 等多種頂級期刊及制藥 Patent 收錄了MCE客戶的科研成果；
•   專業(yè)團隊跟蹤新的制藥及生命科學(xué)研究進展，為您提供*新的活性化合物；
•   與世界各大制藥公司及*科研機構(gòu)建立了長期的合作。